Markers that reliably identify cancer stem cells (CSC) in ovarian cancer could assist prognosis and improve strategies for therapy. CD133 is a reported marker of ovarian CSC. Aldehyde dehydrogenase (ALDH) activity is a reported CSC marker in several solid tumors, but it has not been studied in ovarian CSC. Here we report that dual positivity of CD133 and ALDH defines a compelling marker set in ovarian CSC. 
Introduction
Some tumors follow a cancer stem cell (CSC) model, whereas others do not. In tumors that follow a CSC model, CSCs are believed to make up a limited percentage of the tumor cells, yet be the driving force behind cancer growth (1, 2) . The presence of such cells could explain why cancer often relapses despite a complete clinical remission with initial therapy; with time a few residual treatment-resistant stem cells could repopulate the tumor.
Ovarian cancer is a tumor that commonly shows a complete remission in response to chemotherapy, yet the majority of patients relapse. This suggests that a CSC model may be relevant in ovarian cancer. Supporting the idea of ovarian CSCs, Zhang and colleagues used a primary human ovarian tumor specimen to generate in vitro tumor "spheroids" (3) . One hundred isolated spheroid cells were capable of generating tumors in mice reminiscent of the primary tumor. Tumor spheroids had enriched expression of the stem cell markers CD117 and CD44, suggesting these were possible markers of ovarian CSC. CD133 has also been reported as a marker of ovarian CSC. Limited numbers of CD133 þ cells from ovarian cancer cell lines generated large tumors more rapidly than CD133 À cells, and CD133 þ cells produced tumors in mice with CD133 þ and CD133 À cells (4) . Furthermore, a second group reported that the CD133 þ cell population in the primary human tumor xenografts in mice was primarily responsible for serial tumor passage (5) . Unfortunately, CD133 is only expressed in $40% of ovarian cancer cell lines and $30% of primary ovarian tumors; thus, CD133 may not be a useful CSC marker for a majority of ovarian cancers (4) . Finally, CD24 alone, and in combination with CD44 and EpCAM, was reported to mark cells with ovarian CSC activity in various cancer cell lines (6, 7) . Interestingly, a proportion of these cells also expressed CD133.
Despite these studies of ovarian CSC, several issues remain. To date, no study has isolated an ovarian CSC population directly from human tumors to initiate tumors in mice; all used cell lines, or stem cells isolated from primary cells following in vitro or in vivo passage. This limits the ability to isolate and characterize ovarian CSCs, without concerns for genetic and phenotypic changes associated with the passage of cells.
Recent studies in other solid tumors identified aldehyde dehydrogenase (ALDH) enzymatic activity as a potential marker for CSC. In a study of breast cancer, ALDH þ cells were present in a majority of tumors and capable of directly generating tumors in vivo (8) . Independent studies in colon cancer suggest ALDH identifies colon CSCs; as few as 25 ALDH þ cells could generate tumors whereas ALDH À cells could not (9, 10) . Similarly, ALDH has been proposed as a marker of CSC in leukemia, head and neck, lung, and pancreatic cancers (11) (12) (13) (14) . Interestingly, ALDH has been proposed, together with CD133, to identify CSC population in hepatocellular carcinoma (15) . Based on the evidence for ALDH as a stem cell marker in solid tumors, we performed an extensive analysis of ALDH activity alone, and in combination with CD133, as a marker of ovarian CSC.
Materials and Methods

Tumor processing
Informed consent was obtained from all patients before tissue procurement. All studies were performed with the approval of the Institutional Review Board of the University of Michigan. All tumors were stage III or IV epithelial ovarian or primary peritoneal cancer. Tumors were mechanically dissected into single-cell suspensions and isolated on a ficol gradient as previously described (16) . For ascites, studies of cell pellets were collected by centrifugation, and red cells were lysed using ACK buffer, washed, passed through a 40-mm filter, then passed 4 times through a Standard Hub Pipetting needle to isolate single cells.
Sphere formation
Sphere culture was performed as previously described (8, 17) . Briefly, FACS-isolated ALDH þ/À CD133 þ/À cell populations were plated in triplicate in ultra-low attachment plates in serum-free MEBM-2 (Lonza). Cells were plated at the indicated density and from 1,000 to 10,000 cells/mL in subsequent passage. Sphere formation was assessed 2 weeks after seeding the cells.
Flow cytometric analysis and fluorescence-activated cell sorting Primary ovarian tumor/ascites or cell line single-cell suspensions were counted and incubated with primary antibodies (antibody information for all experiments provided in Supplementary Table S1 (18) (19) (20) . Animals were euthanized when the tumors were approximately 0.5 to 1.0 cm in the largest diameter unless otherwise indicated. Tumors were resected and weighed, and a portion of each tumor was snap frozen for histologic analysis. The remaining portion was processed into a single-cell suspension as described. Tumor volumes were calculated using the L Â W Â W/2 formula. Tumor weights were compared using a Student's T test. Tumor growth curves were compared using ANOVA and a Student t test.
For Immunohistochemistry and microvascular density assessment Fresh tumors were harvested in linear growth phase ($500 mm 3 ) embedded in OCT-Compound (Tissue-Tek) and snap frozen. Seven micrometers of cryosections were processed as previously described (16) . Primary anti-mouse CD31 (1:600) and anti-mouse CD105 (1:200; Supplementary Table S1) were incubated for 2 hours at 20 C. Slides were processed using the Envision system (Dako) per protocol. CD31 and CD105 immunohistochemistry (IHC) were performed on 7 to 11 independent sections of 4 independent ALDH þ or ALDH À cell-derived C. The slides were washed, stained with 4 0 ,6-diaminodo-2-phenylindole, and mounted (ProLong Gold, Molecular probes). Monochrome images of each TMA core were captured with an Olympus BX51 microscope at 3 different extinction/emission wavelengths (DAPI, AF488, and AF648), artificially colored and combined to form images.
Tumors were scored as ALDH
Only cells associated with tumor islets were scored; stromal and vascular staining was not evaluated. The product limit method of Kaplan and Meier was used to estimate overall and recurrence-free survival. Follow-up time was calculated from the date of diagnosis (staging surgery) until the date of death or first disease recurrence for the end points, respectively. Patients not reaching end points were censored on their last known follow-up date. Comparisons in the estimated overall or recurrence-free survival by CD133 and ALDH expression grups were conducted using the log-rank test statistic, P values 5% suggest meaningful differences between groups.
Results
Characterization of ALDH activity in human ovarian tumors and ovarian tumor cell lines
Previous studies reported that CD117/CD44, CD133, CD90, CD24, CD44, and ALDH may identify CSCs in ovarian or other solid tumors (3-5, 8, 21-28) . We analyzed more than 13 primary human ovarian tumors and 5 ascites specimens for these tumor markers. ALDH was the only marker detectable in all primary tumor and ascites (Table 1 ; representative gating provided in Supplementary Fig. S1 ). CD133 expression was detected in 9 of 13 primary tumors. Higher levels of CD133 þ cells were present in ovarian tumor ascites. CD117 was present in only 5 of 11 tumors tested. In contrast, CD44 was expressed at very high levels in all of the tumors tested. CD24 and CD90 showed variable expression.
We also characterized the expression of these CSC markers in human ovarian cancer cell lines. Once again ALDH was the only marker present in all cell lines in a limited subpopulation of cells (Table 1) . At least one cell line expressed very high levels (!40%) of each of the other putative stem cell markers. This may be due to the fact that cell lines may have increased "stemness" associated with in vitro growth selection and passage necessary for the generation of cell lines.
ALDH activity identifies CSC like cells in ovarian tumor cell lines
From our studies, ALDH was the only potential stem cell marker expressed in all primary tumor specimens and detected in limited cellular subpopulations of human primary tumor cells (0.25%-7.78%, (Table 2) . Tumor generation required approximately $9 months. Histological analysis of the xenograft tumors revealed well-differentiated papillary-serous tumors identical to that seen in the primary tumor ( Fig. 2A) . FACS analysis of tumor xenografts revealed robust ALDH þ and ALDH À cell populations (Fig. 2C ).
Similar to cell line studies ALDH þ cell-derived tumors were highly vascular (Fig. 2B) . We have successfully passaged ALDH þ cells from the Pt118 tumor 3 times. These data suggest ALDH activity identifies a population of ovarian cancer cells enriched for CSC activity.
Tumorigenicity of cell lines coexpressing ALDH and CD133
In the hematopoietic system, ALDH used in combination with CD133 improves the identification of stem cells. We next examined the role of ALDH in combination with CD133 in ovarian tumors. FACS confirmed the presence of rare ALDH þ CD133 þ cells in several cell lines (Supplementary À cell tumors (Fig. 3A) . ALDH
þ cell tumors both showed increased microvascular Table 1 . Expression of putative CSC markers in human ovarian tumor samples and cell lines Fig. S3 ).
ALDH-CD133
À negative cells were only able to generate spheres when 100,000 cells were assayed. These spheres were unable to passage suggesting these were adhesive cell clusters rather than true spheres. We next tested the in vivo cancer-initiating ability of ALDH
þ/À cells from primary human ovarian tumors.
From 9 primary tumors tested, we were able to successfully generate tumors from 11, 500, 500, and 500 ALDH þ CD133 þ cells from 4 patients (Pt 32, Pt55, Pt94, and Pt171, respectively; Table 3 ). All 4 of these patient samples showed the greatest tumor sphere generation in the ALDH 
þ cells in the tumor islet, and at least 1 Fig. 4A ). Stromal and vascular staining were excluded. Although we did not observe any correlation with tumor stage, grade, or platinum resistance, Kaplan-Meier analysis showed that patients with ALDH þ CD133 þ tumor cells have worse progression-free and overall survival compared to the other groups individually or combined (Fig. 4B) .
Discussion
ALDH as a marker of ovarian CSC We present here a thorough analysis of ALDH activity, alone and in combination with CD133, as an ovarian CSC marker. This study is the first in ovarian cancer to successfully generate in vivo tumors from a putative stem cell population directly isolated from human tumors. Other studies of ovarian CSC investigated cell lines, used in vitro culture prior to isolation and growth in vivo, or injected total tumor cell suspensions for growth in vivo followed by isolation of stem cells from primary xenografts (4, 5, 32, 33) . Although representing important tools, these manipulations could lead to genetic/phenotypic changes in the CSC population.
Using ALDH and CD133 to define a hierarchy of ovarian CSC In CD133 þ tumors, the combination of ALDH and CD133 appears to enhance ovarian CSC isolation. As few as 11 primary human ALDH þ CD133 þ cells generated tumors in vivo. In addition, we observed an increased tumor engraftment Taking all of our observations together we hypothesize a hierarchical model of ovarian CSC differentiation (Fig. 4C) The combination of ALDH and CD133 to enhance stem cell identification is parallel to the hematopoietic system (34) (35) (36) (37) (38) (39) . Our model is consistent with hematologic malignancies where partially differentiated progenitor cells with self-renewal capacity can manifest stem cell properties (40) (41) (42) ; ALDH is stained in green and CD133 in red. Scale bars indicate 100 mm. Bi and Bii, Kaplan-Meier analysis of overall and recurrence-free survival in 56 patients whose tumors were scored as ALDH as a prognostic factor is controversial with a new report suggesting increased ALDH expression indicates poor prognosis in ovarian cancer (44) . It is possible that stratification of ALDH expression based on CD133 coexpression could explain this discrepancy. 
Improving ovarian CSC growth in vivo
Our study is the first to show the generation of tumor xenografts from CSC directly isolated from primary ovarian carcinoma. However, the tumor generation rate for cells isolated from primary human ovarian tumors was low (20%-40%). This could be secondary to FACS induced cellular toxicity. Alternatively, the s.c. tumor inoculation may be an inferior location for tumor growth; only 50% of glioblastoma stem cells engrafted when implanted s.c., whereas 100% engraftment was obtained when these cells were orthotopically implanted into the cranium (45) . Similarly, increased tumorigenesis was obtained when pancreatic CSCs were injected into the pancreas as opposed to an s.c. site (46) . Finally, use of a humanized microenvironment significantly enhanced engraftment of breast CSC (27) . Thus, future studies using orthotopic CSC injection or a humanized microenvironment for ovarian CSC may increase engraftment rates.
Conclusions
Collectively, our data indicate that ALDH is a marker of CSC in some ovarian tumors that lack CD133 expression. In tumors that express CD133, the combination of ALDH and CD133 can be used to identify a more aggressive CSC suggesting a potential hierarchy of cells with distinct cancer growth potential. Based on this we propose a model of ovarian CSC differentiation similar to that observed for hematopoietic cells.
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